Enzymatica AB Share Price

ENZY

SE0003943620

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 02/07/2026 BST			5-day change	1st Jan Change
2.360 ^SEK	-1.67%		+2.61%	+24.21%

06-24	Enzymatica AB Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article	CI
06-24	Scientific paper on Enzymatica's Berlin II study receives an Expression of Concern, update	FW

Analysts' recommendations: Enzymatica AB

19/07/24	Penser lowers motivated value for Enzymatica - raises required return to reflect risk	FW
26/04/24	Redeye lowers motivated value for Enzymatica to SEK 5.5 (6.0)	FW
20/02/24	Penser lowers Enzymaticas' motivated value	FW
08/11/23	Penser lowers motivated value for Enzymatica	FW
08/11/23	Redeye lowers motivated value for Enzymatica to SEK 6.0 (6.5)	FW

More recommendations

Managers and Directors: Enzymatica AB

Manager	Title	Age	Since
Sana Alajmovic CEO	Chief Executive Officer	-	31/01/2026
Ulf Thomas Blom COO	Chief Operating Officer	61	31/12/2010
Holger Lembrér DFI	Director of Finance/CFO	-	12/04/2026

Director	Title	Age	Since
Gudmundur Palmason CHM	Chairman	58	14/02/2016
Bengt Baron CHM	Chairman	64	18/12/2016
Mats K. Andersson BRD	Director/Board Member	71	18/12/2016

More insiders

Enzymatica AB (publ) is a Sweden-based life science company that develops and sells medical devices for infection-related diseases. The Company deals with research, development and sales of products based on enzyme technology and related activities. Enzymatica AB (publ) develops solutions that support the body's own defenses against virus, irritants and microorganisms. The Company offers products which are based on a barrier technology, includes marine enzymes. Enzymatica AB (publ) focuses on product development based on the tested and patented barrier technology used in the common cold product ColdZyme, a mouth spray that protects against colds, can help shorten the duration of the cold if used in the early stages of infection, relieves cold symptoms, and soothes sore throats.

Employees

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
02/07/26	SEK 2.360	-1.67%	18,303
01/07/26	SEK 2.400	0.00%	48,638
30/06/26	SEK 2.400	-4.38%	155,436
29/06/26	SEK 2.510	+0.40%	26,680
26/06/26	SEK 2.500	+8.70%	209,094

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Cap	573M 501M 460M 429M 813M 54.54B 826M 5.53B 2.14B 26.75B 2.15B 2.1B 92.17B	P/E 2024	-5.73x	P/E 2025	-8.89x
Enterprise Value	541M 473M 434M 405M 767M 51.48B 780M 5.22B 2.02B 25.25B 2.03B 1.99B 87B	EV / Sales 2024	5.88x	EV / Sales 2025	7.96x
Free-Float	56.66%	Yield 2024 *	-	Yield 2025	-

06-24	Enzymatica AB Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article	CI
06-24	Scientific paper on Enzymatica's Berlin II study receives an Expression of Concern, update	FW
06-23	Study of Enzymatica's cold spray Coldzyme gets a warning flag	FW
06-09	Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026	CI
06-09	Enzymatica appoints new Head of Marketing and Sales to drive Coldzyme growth in the Nordics	FW
04-28	Enzymatica Q1 operating loss narrows to SEK 13.6 million	RE
04-28	Enzymatica narrows losses	FW
04-28	Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-01	Enzymatica Marketing Executive sells shares worth over SEK 0.1 million	FW
03-31	Enzymatica, Stada sign partnership agreement for Germany, Austria	RE
03-31	Enzymatica enters into agreement with Stada in Germany	FW
03-31	Enzymatica AB and Stada Arzneimittel Ag Sign Partnership Agreement for Launch and Distribution of Coldzyme Oral Spray Technology in Germany and Austria	CI
02-18	Enzymatica AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

06-24	The evidence base for ColdZyme remains unchanged – PLOS ONE notice concerns the presentation of the Berlin II article, not the evidence base for ColdZyme	AQ
06-09	Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics	AQ
06-08	Enzymatica : partners with Unibet Rose Rockets to put ColdZyme in the Giro d’Italia race routine	PU
05-07	Bulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026	AQ
04-28	Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement	AQ

1 day	-1.67%
1 week	+2.61%
Current month	-1.67%
1 month	-11.94%
3 months	-23.38%
6 months	+22.92%
Current year	+24.21%

1 week	2.31	2.6
1 month	2	2.89
Current year	1.6	3.4
1 year	1.6	3.4
3 years	1.34	5.45
5 years	1.34	13.4
10 years	1.34	24.7

Enzymatica AB Share Price

Stocks

ENZY

SE0003943620

Pharmaceuticals

Valuation: Enzymatica AB

Chart: Enzymatica AB

Latest news : Enzymatica AB

Analysts' recommendations: Enzymatica AB

Press Releases: Enzymatica AB

Quotes and Performance

Course Extremes

Managers and Directors: Enzymatica AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-31	Anna Söderlund	Sell	Responsable ventes & marketing	40,000	0.0165%
12-29	Bengt Baron	Buy	Chairman	20,000	0.0082%
12-26	Bengt Baron	Buy	Chairman	30,000	0.0124%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ENZYMATICA AB	-1.67%	+2.61%	-14.18%	-9.23%	59.3M
ELI LILLY AND COMPANY	+1.86%	+7.65%	+55.77%	+158.84%	1,082B
JOHNSON & JOHNSON	+3.57%	+7.42%	+69.09%	+58.92%	633B
ABBVIE INC.	+3.99%	+7.37%	+36.87%	+93.77%	461B
ROCHE HOLDING AG	-1.20%	-1.94%	+26.41%	+20.22%	339B
ASTRAZENECA PLC	+4.94%	+3.39%	+39.92%	+28.93%	301B
NOVARTIS AG	+2.42%	+1.60%	+30.06%	+42.24%	292B
NOVO NORDISK A/S	+2.47%	+5.18%	-24.80%	-39.60%	225B
AMGEN INC.	+3.55%	+6.05%	+26.04%	+68.52%	202B
GILEAD SCIENCES, INC.	+4.21%	+6.00%	+17.72%	+70.33%	163B
Average	+1.94%	+4.33%	+26.29%	+49.29%	369.98B
Weighted average by Cap.	+1.86%	+5.21%	+41.48%	+80.22%

	2024	2025
Net sales	45.58M 39.82M 36.57M 34.1M 64.65M 4.34B 65.74M 440M 171M 2.13B 171M 167M 7.33B	53.9M 47.1M 43.25M 40.33M 76.46M 5.13B 77.76M 521M 202M 2.52B 202M 198M 8.67B
Net income	-53.18M -46.47M -42.67M -39.79M -75.44M -5.06B -76.71M -514M -199M -2.48B -200M -195M -8.56B	-51.89M -45.34M -41.64M -38.83M -73.61M -4.94B -74.85M -501M -194M -2.42B -195M -191M -8.35B
Net Debt	-73.01M -63.8M -58.58M -54.63M -104M -6.95B -105M -705M -273M -3.41B -274M -268M -11.75B	-32.11M -28.06M -25.77M -24.03M -45.55M -3.06B -46.32M -310M -120M -1.5B -121M -118M -5.17B